BioMark Diagnostics Completes Testing of over 5,400 Subjects as Part of a Validation Study for Early Lung Cancer Detection
Rhea-AI Summary
BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) has successfully completed a major clinical trial for its early lung cancer detection assay. The study, conducted in collaboration with IUCPQ, analyzed over 5,400 patient samples, including 2,500 archived samples and 2,900 high-risk participants. This marks the largest clinical study validating a metabolite-based assay for lung cancer screening.
CEO Rashid Bux highlighted the trial's significance, emphasizing its diverse patient pool and real-world representation. BioMark has partnered with a leading data analytics group to analyze the vast amount of data collected. The company plans to present the results at an upcoming medical conference and submit them for publication in a peer-reviewed journal, aiming to make the innovative technology available to patients as soon as possible.
Positive
- Successful completion of a large-scale clinical trial with over 5,400 patient samples
- Collaboration with a reputable institution (IUCPQ) for the study
- Diverse patient pool including high-risk individuals eligible for lung cancer screening
- Partnership with a leading data analytics group for robust AI and machine learning analysis
- Plans to present results at a medical conference and submit for peer-reviewed publication
Negative
- None.
Largest Clinical Study Validating a Metabolite-based Assay for Lung Cancer Screening
Vancouver, British Columbia--(Newsfile Corp. - September 10, 2024) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF), a leading developer of liquid biopsy tests for early cancer detection, is pleased to announce today the successful completion of a significant clinical trial in collaboration with the Institut Universitaire de Cardiologie et de Pneumologie de Québec (IUCPQ). Over 5,400 patient samples were analyzed using BioMark's innovative lung cancer assay, demonstrating the test's potential to revolutionize early detection and improve patient outcomes.
"This is a pivotal moment for BioMark's early lung cancer assay," said Rashid Bux, CEO and President of BioMark. "The trial launched in February 2022 was designed to encompass a diverse patient pool, including prospectively collected archived samples from about 2,500 patients and enrollment of over 2,900 participants classified as at high risk for lung cancer and eligible for screening in an established and well-defined lung cancer screening cohort. The successful testing of samples representative of the real world is a major milestone for BioMark and underscores the immense potential of our liquid biopsy technology to revolutionize early detection and improve patient outcomes in lung cancer."
BioMark has partnered with a leading data analytics group possessing robust artificial intelligence and machine learning capabilities to analyze the vast amount of data collected during the trial. The results of the study will be presented at an upcoming medical conference and submitted for publication in a peer-reviewed journal. BioMark is committed to advancing the development of its lung cancer assay and making it available to patients in need as soon as possible. This innovative technology has the potential to significantly improve early detection rates and treatment outcomes for this devastating disease.
About BioMark Diagnostics Inc.
BioMark Diagnostics Inc. is a leading developer of liquid biopsy tests for the early detection of cancer that leverages the power of metabolomics and machine learning algorithms. The company's proprietary technology utilizes a simple blood draw to detect the presence of cancer-associated biomarkers, enabling earlier diagnosis and improved patient outcomes. The technology can also be used for measuring response to treatment and potentially for serial monitoring of cancer survivors. BioMark is committed to developing innovative and accessible diagnostic solutions to address unmet medical needs in oncology.
Further information about BioMark is available under its profile on the SEDAR+ website www.sedarplus.ca and the CSE website https://thecse.com/.
For further information on BioMark, please Contact:
Rashid Ahmed Bux
President & CEO
BioMark Diagnostics Inc.
Tel. 604-370-0779
Email: info@biomarkdiagnostics.com
Forward-Looking Information:
This press release may include forward-looking information within the meaning of Canadian securities legislation, concerning the business of BioMark. Forward-looking information is based on certain key expectations and assumptions made by the management of BioMark. Although BioMark believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because BioMark can give no assurance that they will prove to be correct. Forward-looking statements contained in this press release are made as of the date of this press release. BioMark disclaims any intent or obligation to update publicly any forward-looking information, whether as a result of new information, future events, or results or otherwise, other than as required by applicable securities laws.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/222771
FAQ
How many patient samples were analyzed in BioMark Diagnostics' lung cancer detection study?
What is the significance of BioMark's (BMKDF) recent clinical trial for lung cancer detection?
When did BioMark Diagnostics (BMKDF) launch the lung cancer detection trial?
What are BioMark's (BMKDF) plans for the results of their lung cancer detection study?
